Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92,107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T, Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X, Rivera VM. Gonzalvez F, et al. Among authors: li f, li s. Cancer Discov. 2021 Jul;11(7):1672-1687. doi: 10.1158/2159-8290.CD-20-1683. Epub 2021 Feb 25. Cancer Discov. 2021. PMID: 33632773
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross DAE, Wong KK. Liu S, et al. Among authors: li s. Clin Cancer Res. 2018 Jun 1;24(11):2594-2604. doi: 10.1158/1078-0432.CCR-17-1875. Epub 2018 Jan 3. Clin Cancer Res. 2018. PMID: 29298799 Free PMC article.
Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
Han H, Li S, Chen T, Fitzgerald M, Liu S, Peng C, Tang KH, Cao S, Chouitar J, Wu J, Peng D, Deng J, Gao Z, Baker TE, Li F, Zhang H, Pan Y, Ding H, Hu H, Pyon V, Thakurdin C, Papadopoulos E, Tang S, Gonzalvez F, Chen H, Rivera VM, Brake R, Vincent S, Wong KK. Han H, et al. Among authors: li f, li s. Cancer Res. 2021 Oct 15;81(20):5311-5324. doi: 10.1158/0008-5472.CAN-21-1526. Epub 2021 Aug 11. Cancer Res. 2021. PMID: 34380634 Free PMC article.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Robichaux JP, et al. Among authors: li s. Nat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23. Nat Med. 2018. PMID: 29686424 Free PMC article.
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.
Tang KH, Li S, Khodadadi-Jamayran A, Jen J, Han H, Guidry K, Chen T, Hao Y, Fedele C, Zebala JA, Maeda DY, Christensen JG, Olson P, Athanas A, Loomis CA, Tsirigos A, Wong KK, Neel BG. Tang KH, et al. Among authors: li s. Cancer Discov. 2022 Jan;12(1):47-61. doi: 10.1158/2159-8290.CD-21-0369. Epub 2021 Aug 5. Cancer Discov. 2022. PMID: 34353854 Free PMC article.
Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.
Hai J, Liu S, Bufe L, Do K, Chen T, Wang X, Ng C, Li S, Tsao MS, Shapiro GI, Wong KK. Hai J, et al. Among authors: li s. Clin Cancer Res. 2017 Nov 15;23(22):6993-7005. doi: 10.1158/1078-0432.CCR-17-1098. Epub 2017 Aug 18. Clin Cancer Res. 2017. PMID: 28821559 Free PMC article.
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, Leggett AL, Li T, Wang Y, Zhang T, Kim TJ, Hong SH, Poudel-Neupane N, Silkes M, Mudianto T, Tan L, Shimamura T, Meyerson M, Bass AJ, Watanabe H, Gray NS, Young RA, Wong KK, Hammerman PS. Rusan M, et al. Among authors: li s, li t, li y, li k. Cancer Discov. 2018 Jan;8(1):59-73. doi: 10.1158/2159-8290.CD-17-0461. Epub 2017 Oct 20. Cancer Discov. 2018. PMID: 29054992 Free PMC article.
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.
Adeegbe DO, Liu S, Hattersley MM, Bowden M, Zhou CW, Li S, Vlahos R, Grondine M, Dolgalev I, Ivanova EV, Quinn MM, Gao P, Hammerman PS, Bradner JE, Diehl JA, Rustgi AK, Bass AJ, Tsirigos A, Freeman GJ, Chen H, Wong KK. Adeegbe DO, et al. Among authors: li s. Cancer Immunol Res. 2018 Oct;6(10):1234-1245. doi: 10.1158/2326-6066.CIR-18-0077. Epub 2018 Aug 7. Cancer Immunol Res. 2018. PMID: 30087114 Free PMC article.
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK. Deng J, et al. Among authors: li s. Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3. Cancer Discov. 2018. PMID: 29101163 Free PMC article.
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.
Ivanova E, Kuraguchi M, Xu M, Portell AJ, Taus L, Diala I, Lalani AS, Choi J, Chambers ES, Li S, Liu S, Chen T, Barbie TU, Oxnard GR, Haworth JJ, Wong KK, Dahlberg SE, Aref AA, Barbie DA, Bahcall M, Paweletz CP, Jänne PA. Ivanova E, et al. Among authors: li s. Clin Cancer Res. 2020 May 15;26(10):2393-2403. doi: 10.1158/1078-0432.CCR-19-1844. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034078 Free PMC article.
92,107 results
You have reached the last available page of results. Please see the User Guide for more information.